Vinod Subramanian’s Post

New Frontiers in Technology: AI Use in Clinical Trial Patient Recruitment in Health Systems: AI is significantly enhancing the efficiency of identifying and enrolling patients. #finance #pharmacy #lifesciences

Digital Twins - Accelerating drug development in number of ways.

🌟 Exciting News! 🌟 Did you know that IMC's CertiScan AI (Adherence Insights) solution can predict PK/PD based on patient adherence data from smart medication packaging? This innovative technology has the potential to transform the way we approach clinical therapies. Another incredible benefit? IMC's CertiScan AI not only is able to predict PK/PD but also eliminates costly and inconvenient lab work, particularly in remote trials. This advancement enhances efficiency and accessibility in clinical research. “a compound with a short half‐life, a delayed onset of its PD effect, onset, and combined with poor adherence may result in a trial outcome that fails to demonstrate a significant difference compared to the placebo group, resulting in a type II statistical error, unless sample sizes are very large.” (See https://lnkd.in/drxt2YgF) Addressing non-adherence through CertiScan AI is key to ensuring trial success and preventing wastage of resources. By utilizing adherence data points, CertiScan AI empowers healthcare professionals to make informed decisions and optimize patient outcomes. #Clincialtrials #certiscan #medicationadherence

🔍 Insisting on Accurate Data to Prevent Type 2 Failures in Clinical Trials Objective medication adherence data points are crucial for preventing Type 2 failures. With IMC's CertiScan AI, researchers can ensure reliable outcomes and avoid misleading results. Let's prioritize accurate data for successful clinical trials! #ClinicalResearch #AdherenceData #CertiScan #smartpackaging #clinicaltrials #medicationadherence

FDA used AI for regulatory decision making?! Learn more by checking out the article below… This is an interesting story of how CDER staff combined the predictive ability of AI with validation processes to identify the patient population most likely to benefit from a new drug.

Digital twins can support the industry to overcome longstanding challenges faced in patient recruitment, the ethical issues associated with placebo arms, and the impact these constraints have on cycle and approval times. Phesi have demonstrated that digital twins offer real potential to replace standard-of-care comparator arms to streamline the implementation of clinical trials and dramatically reduce patient burden, by improving clinical trial design and investigator site enrollment, aligned with precision medicine at the age of AI. We are grateful of the opportunity to have collaborated with Professor Yi-Bin Chen. #DigitalTwins #HealthcareInnovation #ClinicalTrials #PrecisionMedicine #AI

This virtual workshop focuses on using AI for clinical drug development to match candidate drugs to patient benefits, predict drug safety, find potential drug combinations, and identify promising drug repurposing opportunities. The session introduces TxGNN, a knowledge graph for predicting therapeutic uses across diseases, highlighting its potential for drug repurposing in rare diseases. This segment illustrates AI's role in developing new therapies, ensuring they are delivered to the right patient at the right time, and achieving consistent medicinal effects. #AI #drugdevelopment #medaff

🚀 Revolutionizing Clinical Trial Site Selection with AI 💡 Clinical trials are essential to bring new drugs to market, but poor site selection can cause costly delays. With 90% of trials failing to meet timelines, it's time for a change. Excited to share my article on how AI solutions can identify high-performing sites, improving recruitment speed, cost efficiency which leads to streamline clinical trials process and drug development. Link: https://lnkd.in/enF274qf #healthoutcomes #RWE #ClinicalTrials #AI #AgenticAI #Exl #makingsenseofmachinelearning

We've seen time and time again how AI is reshaping drug discovery by enabling faster, more precise identification of therapeutic targets and optimizing the design of new medications, therefore significantly reducing both time and costs in the process. But beyond development time and costs, it can also increase the accuracy and efficacy of treatments. This overall improvement can potentially lead to better overall patient health, as we further develop precision medicine tailored to individual patient needs. We can definitely hope that with increased ease of production and development, access to the general public will increase, but only time will tell. #AI #DrugDiscovery #DrugDevelopment #PrecisionMedicine

It is important to note that along with the recent FDA approvals of earlier line clinical use of both #Carvykti and #Abecma, that the FDA also signed off on expanded manufacturing release specifications for Carvykti. As part of the application, the J&J/Legend reported they submitted to the FDA “a wealth of what I call the sensitivity analysis by correlating the release spec with the clinical outcome,” said Legend CEO Ying Huang. With a wider specification, they are expected to improve supply by further reducing the manufacturing failure rate. https://lnkd.in/guimz64C In a presentation at the Cambridge Healthtech Institute #SCOPE conference in February, a J&J Innovative Medicine team presented work they were doing on a project they entitled "Med.ai CAR-T" which was integrating data across their entire platform (patient-collection-QC-mfg-clinical) to facilitate cross-functional data analysis in support of manufacturing optimization using advanced analytics and machine learning to identify multimodal makers capable of improving performance and predicting manufacturing success. #CART #celltherapy #FDA #approvals #manufacturing #artificialintelligence #AI #machinelearning #ML #analytics